.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Cerilliant
Fuji
Teva
Argus Health
Federal Trade Commission
Accenture
Cantor Fitzgerald
QuintilesIMS

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,759,308

« Back to Dashboard

Which drugs does patent 7,759,308 protect, and when does it expire?


Patent 7,759,308 protects SIGNIFOR LAR and is included in one NDA.

This patent has thirty-seven patent family members in thirty-two countries.

Summary for Patent: 7,759,308

Title:Microparticles comprising somatostatin analogues
Abstract: Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.
Inventor(s): Ahlheim; Markus (Staufen, DE), Ausborn; Michael (Lorrach, DE), Lambert; Olivier (Spechbach-le-Haut, FR), Riemenschnitter; Marc (Freiburg, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:10/579,186
Patent Claim Types:
see list of patent claims
Compound; Composition; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-001Dec 15, 2014RXYesNo► Subscribe► SubscribeY
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-002Dec 15, 2014RXYesNo► Subscribe► SubscribeY
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-003Dec 15, 2014RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,759,308

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0326602.0Nov 14, 2003
United Kingdom0406241.0Mar 19, 2004
PCT Information
PCT FiledNovember 12, 2004PCT Application Number:PCT/EP2004/012870
PCT Publication Date:May 26, 2005PCT Publication Number: WO2005/046645

Non-Orange Book Patents for Patent: 7,759,308

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,188,037Microparticles comprising somatostatin analogues► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,759,308

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2541944► Subscribe
China1878541► Subscribe
Cyprus1110293► Subscribe
Germany602004025271► Subscribe
Denmark1686964► Subscribe
EcuadorSP066565► Subscribe
European Patent Office1686964► SubscribeC300716Netherlands► Subscribe
European Patent Office1686964► SubscribePA2015009Lithuania► Subscribe
European Patent Office1686964► SubscribeCA 2015 00026Denmark► Subscribe
European Patent Office1686964► Subscribe92701Luxembourg► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Argus Health
Cantor Fitzgerald
Dow
Chubb
AstraZeneca
Novartis
Teva
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot